The Relationship between tumor blood flow, angiogenesis, tumor hypoxia, and aerobic glycolysis

Cancer Research

Volumn 73, Issue 18, 2013, Pages 5618-5624

  Østergaard, Leif ^a,b   Tietze, Anna ^a,b   Nielsen, Thomas ^b   Drasbek, Kim Ryun ^a   Mouridsen, Kim ^a   Jespersen, Sune Nørhøj ^a   Horsman, Michael R ^b  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; OXYGEN;

AEROBIC GLYCOLYSIS; AEROBIC METABOLISM; ANTIANGIOGENIC THERAPY; BLOOD VESSEL PARAMETERS; BREAST CARCINOMA; CANCER TISSUE; CAPILLARY TRANSIT TIME HETEROGENEITY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; ECHOGRAPHY; FLOW KINETICS; HEMODYNAMICS; HUMAN; HYPOXIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION;

ANIMALS; ANOXIA; GLYCOLYSIS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN; REGIONAL BLOOD FLOW;

EID: 84884755163     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0964     Document Type: Review

References (30)

1. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
3. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76.
4. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
5. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30(5 Suppl 16):117-24.
6. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.NEngl J Med 2004;350:2335-42.
7. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011;91:1071-121.
8. Horsman MR, Siemann DW. Pathophysiologic effects of vasculartargeting agents and the implications for combination with conventional therapies. Cancer Res 2006;66:11520-39.
9. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
10. Fukumura D, Duda DG, Munn LL, Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in preclinical models. Microcirculation 2010;17:206-25.
11. Siemann DW, Dai Y, Horsman MR. Hypoxia, metastasis, and antiangiogenic therapies In: Melilli G, editor. Hypoxia and cancer: biological implications and therapeutic opportunities. New York: Springer; 2013.
12. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989;49:6449-65.
13. Vaupel P, Hockel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 2007; 9:1221-35.
14. Vaupel P, Hoeckel M, Mayer A. Oxygenation status of urogenital tumors. Adv Exp Med Biol 2011;701:101-6.
15. Vaupel P, Kelleher DK. Blood flow and oxygenation status of gastrointestinal tumors. Adv Exp Med Biol 2012;737:133-8.
16. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004;14:198-206.
17. Pries AR, Cornelissen AJ, Sloot AA, Hinkeldey M, Dreher MR, Hopfner M, et al. Structural adaptation and heterogeneity of normal and tumor microvascular networks. PLoS Comput Biol 2009;5:e1000394.
18. Pries AR, Hopfner M, le Noble F, Dewhirst MW, Secomb TW. The shunt problem: control of functional shunting in normal and tumour vasculature. Nat Rev Cancer 2010;10:587-93.
19. Renkin EM. B. W. zweifach award lecture. regulation of the microcirculation. Microvasc Res 1985;30:251-63.
20. Jespersen SN, Østergaard L. The roles of cerebral blood flow, capillary transit time heterogeneity and oxygen tension in brain oxygenation and metabolism. J Cereb Blood Flow Metab 2012;32:264-77.
21. Warburg O, Posener K, Negelin E. Uber den stoffwechsel der tumoren. Biochem Z 1924;152:319-44.
22. Østergaard L, Sorensen AG, Chesler DA, Weisskoff RM, Koroshetz WJ,WuO, et al. Combined diffusion-weighted and perfusion-weighted flow heterogeneity magnetic resonance imaging in acute stroke. Stroke 2000;31:1097-103.
23. Quarles CC, Schmainda KM. Assessment of the morphological and functional effects of the anti-angiogenic agent SU11657 on 9L gliosarcoma vasculature using dynamic susceptibility contrast MRI. Magn Reson Med 2007;57:680-7.
24. King RB, Raymond GM, Bassingthwaighte JB. Modeling blood flow heterogeneity. Ann Biomed Eng 1996;24:352-72.
25. Stewart GN. Researches on the circulation time in organs and on the influences which affect it. Parts I-III. J Physiol 1894;15:1-89.
26. Kallinowski F, Schlenger KH, Runkel S, Kloes M, Stohrer M, Okunieff P, et al. Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res 1989;49:3759-64.
27. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
28. Østergaard L, Chesler DA, Weisskoff RM, Sorensen AG, Rosen BR. Modeling cerebral blood flow and flow heterogeneity from magnetic resonance residue data. J Cereb Blood Flow Metab 1999;19:690-9.
29. Østergaard L. Principles of cerebral perfusion imaging by bolus tracking. J Magn Reson Imaging 2005;22:710-7.
30. Mouridsen K, Østergaard L, Christensen S, Jespersen SN. Reliable estimation of capillary transit time distributions at voxel level using DSC MRI. In: Proceedings of the International Society of Magnetic Resonance in Medicine; 2011 May 7-13; Montréal, Canada. International Society of Magnetic Resonance in Medicine; 2011. p 3915.